# ZVSA (Zyversa Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Zyversa Therapeutics, Inc. reported $742K in total assets and a net loss of $24.49M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ZVSA
- Markdown: https://convexityos.com/fundamentals/ZVSA.md
- SEC CIK: 0001859007
- Reporting currency: USD
- Latest filing period: March 31, 2026
- Last synced: Nov 21, 2026, 05:16 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001859007&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$24.65M | Operating profit |
| Net Income | FY 2025 | -$24.49M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$3.02 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Mar 31, 2026 | $303K | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Research & Development | $1.11M | $1.78M | $3.21M | $5.41M |
| Total Operating Expenses | $25.49M | $9.14M | $107.8M | $13.01M |
| **Operating Income** | -$25.49M | -$9.14M | -$107.8M | -$13.01M |
| **EBITDA** | -- | -$9.13M | -$107.7M | -$13.00M |
| Income Before Tax | -$25.80M | -$9.41M | -$107.8M | -$14.05M |
| Income Tax Expense | -$852K | $6.7K | -$9.46M | -- |
| **Net Income** | -$24.95M | -$9.41M | -$98.30M | -$14.05M |
| Basic EPS | -$4.18 | -$8.48 | -$1,089.70 | -$1,101,223.58 |
| **Diluted EPS** | -$4.18 | -$8.48 | -$1,089.70 | -$1,101,223.58 |
| Basic Shares Outstanding | 6.0M | 1.1M | 97.5K | 22 |
| Diluted Shares Outstanding | 6.0M | 1.1M | 97.5K | 22 |

### Income Statement (Quarterly)

| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $58K | $79K | $365K | $410K | $259K | $121K | $436K | $709K |
| Total Operating Expenses | $1.30M | $552K | $20.75M | $2.04M | $2.14M | $1.29M | $2.27M | $2.75M |
| **Operating Income** | -$1.30M | -$552K | -$20.75M | -$2.04M | -$2.14M | -$1.29M | -$2.27M | -$2.75M |
| **EBITDA** | -- | -- | -- | -- | -- | -$1.29M | -$2.27M | -$2.75M |
| Income Before Tax | -- | -- | -$20.66M | -$2.21M | -- | -$1.42M | -$2.40M | -$2.75M |
| Income Tax Expense | -- | -- | -$852K | -- | -- | -- | -- | $9.7K |
| **Net Income** | -$1.79M | -$679K | -$19.81M | -$2.21M | -$2.26M | -$1.42M | -$2.40M | -$2.76M |
| Basic EPS | -$0.22 | -- | -$2.56 | -$0.46 | -$0.73 | -- | -$2.43 | -$3.31 |
| **Diluted EPS** | -$0.22 | -- | -$2.56 | -$0.46 | -$0.73 | -- | -$2.43 | -$3.31 |
| Basic Shares Outstanding | 8.1M | -- | 7.7M | 4.8M | 3.1M | -- | 988.4K | 834.9K |
| Diluted Shares Outstanding | 8.1M | -- | 7.7M | 4.8M | 3.1M | -- | 988.4K | 834.9K |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $102K | $1.53M | $3.14M | $5.90M | $928K |
| **Cash & Short-Term Investments** | $102K | $1.53M | $3.14M | $5.90M | $928K |
| **Total Current Assets** | $463K | $1.72M | $3.35M | $6.36M | $1.18M |
| Property, Plant & Equipment, Net | -- | -- | $6.9K | $17K | -- |
| Goodwill | -- | -- | -- | $11.90M | -- |
| Intangible Assets | -- | -- | -- | $100.1M | -- |
| Other Non-Current Assets | -- | $18.65M | $18.65M | $100.1M | -- |
| **Total Non-Current Assets** | $0 | $18.88M | $18.76M | $112.1M | $75.96M |
| **Total Assets** | $463K | $20.60M | $22.11M | $118.5M | $77.14M |
| Accounts Payable | $10.12M | $9.34M | $8.43M | $6.03M | -- |
| **Total Current Liabilities** | $12.85M | $11.23M | $10.19M | $8.19M | $277K |
| **Total Non-Current Liabilities** | $0 | $852K | $845K | $10.32M | $3.38M |
| **Total Liabilities** | $12.85M | $12.08M | $11.04M | $18.51M | $3.65M |
| **Total Debt (incl. Leases)** | -- | -- | $8.7K | $109K | -- |
| Common Stock | $809 | $251 | $40 | $26 | $32 |
| Retained Earnings | -$137.6M | -$112.6M | -$103.2M | -$4.92M | -$2.26M |
| **Total Stockholders' Equity** | -$12.39M | $8.52M | $11.07M | $99.66M | -$2.26M |
| Total Equity | -$12.39M | $8.52M | $11.07M | $99.66M | -$2.26M |

### Balance Sheet (Quarterly)

| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $303K | $102K | $528K | $72K | $1.61M | $1.53M | $123K | $119K |
| **Cash & Short-Term Investments** | $303K | $102K | $528K | $72K | $1.61M | $1.53M | $123K | $119K |
| **Total Current Assets** | $742K | $463K | $996K | $549K | $2.11M | $1.72M | $390K | $641K |
| Property, Plant & Equipment, Net | -- | -- | -- | -- | -- | -- | -- | $1.7K |
| Other Non-Current Assets | -- | -- | -- | -- | $18.65M | $18.65M | $18.65M | $18.65M |
| **Total Non-Current Assets** | $0 | $0 | $45K | $19.09M | $18.88M | $18.88M | $19.03M | $18.83M |
| **Total Assets** | $742K | $463K | $1.04M | $19.64M | $20.99M | $20.60M | $19.42M | $19.47M |
| Accounts Payable | $10.24M | $10.12M | $9.81M | $9.77M | $9.60M | $9.34M | $9.28M | $8.32M |
| **Total Current Liabilities** | $14.87M | $12.85M | $12.77M | $12.69M | $12.00M | $11.23M | $11.54M | $9.99M |
| **Total Non-Current Liabilities** | $0 | $0 | $0 | $852K | $852K | $852K | $855K | $855K |
| **Total Liabilities** | $14.87M | $12.85M | $12.77M | $13.54M | $12.86M | $12.08M | $12.40M | $10.85M |
| Common Stock | $809 | $809 | $809 | $487 | $257 | $251 | $107 | $83 |
| Retained Earnings | -$139.4M | -$137.6M | -$136.9M | -$117.1M | -$114.9M | -$112.6M | -$111.2M | -$108.8M |
| **Total Stockholders' Equity** | -$14.12M | -$12.39M | -$11.73M | $6.10M | $8.13M | $8.52M | $7.03M | $8.62M |
| Total Equity | -$14.12M | -$12.39M | -$11.73M | $6.10M | $8.13M | $8.52M | $7.03M | $8.62M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$24.95M | -$9.41M | -$98.30M | -$14.05M |
| Depreciation & Amortization | -- | $6.9K | $10K | $9.9K |
| Stock-Based Compensation | $223K | $706K | $1.19M | $3.52M |
| Change in Payables | $689K | $889K | $2.41M | $6.62M |
| **Operating Cash Flow** | -$5.11M | -$7.52M | -$8.72M | -$1.49M |
| Common Stock Issued | -- | $1.35M | -- | -- |
| **Financing Cash Flow** | $3.69M | $5.91M | $5.96M | $1.87M |
| **Net Change in Cash** | -$1.43M | -$1.61M | -$2.76M | $371K |

### Cash Flow Statement (Quarterly)

| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$1.79M | -$679K | -$19.81M | -$2.21M | -$2.26M | -$1.42M | -$2.40M | -$2.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- | $0 | $1.7K | $2.6K |
| Stock-Based Compensation | $56K | $17K | $74K | -$22K | $154K | $161K | $161K | $161K |
| Change in Payables | $112K | $318K | $315K | -$135K | $191K | $212K | $791K | $189K |
| **Operating Cash Flow** | -$799K | -$414K | -$1.41M | -$1.52M | -$1.77M | -$1.21M | -$614K | -$1.91M |
| **Financing Cash Flow** | $1.00M | -$13K | $1.86M | -$18K | $1.85M | $2.62M | $618K | $0 |
| **Net Change in Cash** | $201K | -$426K | $456K | -$1.54M | $81K | $1.41M | $3.4K | -$1.91M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -110.5% | -887.6% | -14.1% |
| Return on Assets (ROA) | -5384.0% | -45.7% | -444.5% | -11.9% |
| Current Ratio | 0.04x | 0.15x | 0.33x | 0.78x |
| Quick Ratio | 0.01x | 0.14x | 0.31x | 0.72x |
| Debt to Equity | -- | -- | 0.00x | 0.00x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -- | -- | -135.9% | -108.8% | -110.5% | -303.5% | -253.3% |
| Return on Assets (ROA) | -3299.4% | -5384.0% | -2470.1% | -42.2% | -42.1% | -45.7% | -109.8% | -112.1% |
| Current Ratio | 0.05x | 0.04x | 0.08x | 0.04x | 0.18x | 0.15x | 0.03x | 0.06x |
| Quick Ratio | 0.02x | 0.01x | 0.04x | 0.01x | 0.13x | 0.14x | 0.01x | 0.01x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
